Parkinson's disease, Restless legs syndrome.

Ropinirole is a non-ergoline dopamine subtype selective agonist, and exerts activity in the CNS at D 2 and D 3 receptors, but have no activity at the D1 receptor.

Bioavailability: 55% because of firs-pass metabolism; protein binding 10 to 40%; extensively metabolized in liver via CYP1A2 to inactive metabolites; elimination half-life: 6 hours.

hypersensitivity to ropinirole product

C

not recommended

Common: nausea, vomiting, dizziness, fatigue, headache, edema of leg, and increased sweating. Serious: Orthostatic hypotension, syncope, dyskinesia, sleep attack, somnolence, and hallucinations.

Parkinson's disease: initial, 0.25 mg orally 3 times daily. It should be titrated weekly to therapeutic response; ascending dose schedule: week 1, 0.25 mg 3 times daily; week 2, 0.5 mg 3 times daily; week 3, 0.75 mg 3 times daily; week 4, 1 mg 3 times daily; after week 4, if necessary, may increase daily dosage by 1.5 mg/day on weekly basis up to 9 mg/day, then by up to 3 mg/day weekly to total dose of 24 mg/day. Restless legs syndrome: Dose titration (all doses are once daily 1 to 3 hours before bedtime), 0.25 mg for days 1 and 2; 0.5 mg for days 3-7; 1 mg for week 2; 1.5 mg for week 3; 2 mg for week 4; 2.5 mg for week 5; 3 mg for week 6; 4 mg for week 7.